A recent study has reported that tumor-expressed FcγRIIb could confer the drug-resistance to patients who had diffuse large B-cell lymphoma in the treatment of immunochemotherapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone), and it was also correlated with poor prognosis of those patients (Nowicka et al., 2021). Here, FCGR2B is linked to neoplasm.